Vivek Nadkarni, MD
Nephrology · Elyria, OHNPI 1598791238
Payments from drug & device makers
Across 121 payments — averaging $33.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$596
- Amgen$441
- Otsuka America Pharmaceutical, Inc.$427
- Bard Peripheral Vascular, Inc.$394
- Mallinckrodt Hospital Products Inc.$373
- Travere Therapeutics, Inc.$283
- plus $2K from 22 others
What the payments were for
- Travel & lodging$271%
- Food & beverage$3,72192%
- Education$2827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $596 |
| Amgen(2 entities) | 15 | $441 |
| Otsuka America Pharmaceutical, Inc. | 15 | $427 |
| Bard Peripheral Vascular, Inc. | 6 | $394 |
| Mallinckrodt Hospital Products Inc. | 6 | $373 |
| Travere Therapeutics, Inc. | 16 | $283 |
| W. L. Gore & Associates, Inc. | 1 | $213 |
| Fresenius USA Marketing, Inc. | 9 | $180 |
| Angiodynamics, Inc. | 1 | $179 |
| Nxstage Medical, Inc. | 3 | $127 |
| GSK | 3 | $117 |
| Boehringer Ingelheim | 1 | $90 |
| Aurinia Pharma U.S., Inc. | 3 | $87 |
| Calliditas Therapeutics US Inc. | 6 | $86 |
| Esperion Therapeutics, Inc. | 1 | $82 |
| Ascendis Pharma Endocrinology Inc | 3 | $73 |
| Novartis | 3 | $46 |
| Baxter Healthcare | 1 | $40 |
| Vifor Pharma, Inc. | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Bayer | 2 | $26 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Akebia Therapeutics Inc | 1 | $18 |
| Sanofi | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,030 in reported general payments places this provider in the 70th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 59 | $77,146 |
| FarxigaDapagliflozin Propanediol | 72 | $56,103 |
| VelphoroSucroferric Oxyhydroxide | 26 | $52,253 |
| OzempicSemaglutide | 23 | $26,460 |
| Lanthanum Carbonate | 17 | $18,147 |
| EntrestoSacubitril/Valsartan | 16 | $12,259 |
| Sevelamer Carbonate | 41 | $6,582 |
| JardianceEmpagliflozin | 11 | $6,555 |
| TradjentaLinagliptin | 12 | $5,590 |
| Calcitriol | 191 | $3,203 |
| Torsemide | 156 | $2,855 |
| Potassium Citrate ErPotassium Citrate | 22 | $2,668 |
| Calcium Acetate | 29 | $2,234 |
| Hydralazine Hcl | 89 | $1,568 |
| Potassium Chloride | 75 | $1,516 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $18 | $77,14659 claims |
| AstraZenecaFarxiga | $596 | $56,10372 claims |
| Fresenius USA Marketing, Inc.Velphoro | $180 | $52,25326 claims |
| Novo NordiskOzempic | $14 | $26,46023 claims |
| NovartisEntresto | $46 | $12,25916 claims |
| Boehringer IngelheimJardiance, Tradjenta | $90 | $12,14523 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $30 | $76735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 nephrology providers in Ohio.
Other nephrology in Elyria
- Isabelle AyoubColumbus$1.6M
- Andrew LazarBeachwood$806K
- Samir ParikhColumbus$699K
- Brad RovinColumbus$625K
- Lance DworkinToledo$601K
- Mohamed SekkarieToledo$524K
- Kevin SchroederColumbus$518K
- Prabir Roy ChaudhuryCincinnati$483K
- Amit GovilCincinnati$444K
- Sankar NavaneethanCleveland$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.